Vilon (Lys-Glu) | Pen

Vilon (Lys-Glu) is a peptide positioned for controlled research settings where thymus-linked immune regulation is being studied in relation to T-cell differentiation markers, immune aging and resilience endpoints, and inflammation/oxidative-stress signaling outputs.

Supports

1. T-cell differentiation marker expression (e.g., CD4/CD5-linked readouts) in thymic cell models
2. Immune aging endpoints in thymus/spleen-focused animal paradigms
3. Apoptosis–proliferation balance in immune-cell cultures under stress conditions
4. DNA-binding / transcriptional regulation hypotheses for ultrashort peptides (model dependent)
5. Innate–adaptive immune crosstalk outputs (cytokine-linked signaling) in controlled assays

Description

Vilon is commonly described as the synthetic dipeptide L-lysyl-L-glutamic acid (Lys-Glu; “KE”), categorized within ultrashort peptide bioregulators. In experimental immunology frameworks, it is used as a sequence-defined tool to probe thymus-associated immune regulation, particularly processes connected to T-cell maturation and immune homeostasis.

Across mechanistic and preclinical sources, Vilon is discussed in the context of immunoprotective activity during aging, stress exposure, and recovery models. Reported observations include modulation of thymic cell differentiation markers and effects on thymus/spleen aging phenotypes in animal paradigms, supporting its use in study designs that quantify immune-cell differentiation, proliferation/apoptosis balance, and downstream immune function signals.

Because immune responses are highly dependent on baseline state, age, and challenge conditions, Vilon is best positioned for controlled research protocols with clearly defined endpoints (cell markers, transcription outputs, and functional immune readouts) and appropriate comparator controls.

Clinical Status

Evidence relevant to Vilon includes mechanistic literature on ultrashort peptide gene-expression regulation, in vitro thymic cell studies reporting differentiation-marker shifts, and multiple animal-model observations (e.g., thymus/spleen aging changes under stressors such as low-dose irradiation; carcinogenesis models). Human clinical literature exists in regional medical sources where Vilon is included as an immunomodulator in complex treatment contexts, but robust regulator-approved clinical status is not established in the provided raw text.

Evidence type:
Human RCT ☐ | Observational ✔ | Animal ✔ | In vitro ✔ | Regulatory approval ☐

Mechanism of Action

Ultrashort peptides such as Lys-Glu are commonly framed as modulators of gene expression and protein synthesis, with proposed mechanisms that include sequence-dependent interactions with nucleic acids and chromatin-associated targets. Within this framework, Vilon is discussed as capable of binding specific DNA motifs in mechanistic sources, supporting transcription-focused endpoint selection in experimental designs.

In thymus-linked immune models, Vilon has been reported to increase expression of lymphocyte differentiation markers in thymic cells and to influence immune aging trajectories in thymus/spleen systems. Mechanistic study designs often integrate T-cell marker panels (e.g., CD4/CD5-linked readouts), apoptosis/proliferation indices, cytokine-linked outputs, and oxidative-stress markers to contextualize observed immune shifts under defined challenges.

Benefits

• Thymus-focused immune regulation probe:
  Used to study thymus-associated immune programming and T-cell maturation endpoints in controlled models.
• T-cell differentiation marker tracking:
  Supports protocols monitoring CD4/CD5-linked readouts and related differentiation signatures in thymic cell systems.
• Immune aging and resilience frameworks:
  Applicable to animal paradigms assessing thymus/spleen aging phenotypes under stressors and during recovery windows.
• Apoptosis/proliferation balance mapping:
  Fits designs evaluating whether immune-cell survival vs. proliferation shifts contribute to functional immune outcomes.
• Transcriptional regulation hypothesis testing:
  Aligns with ultrashort-peptide literature describing DNA-binding and gene-expression modulation mechanisms.
• Comparator within peptide bioregulator sets:
  Useful as a defined dipeptide reference when comparing thymus-directed peptide sequences across shared endpoint panels.

Research Data

Stack Suggestions

In extended experimental designs, Vilon (Lys-Glu) is sometimes paired with:

• Tymogen (Glu-Trp) → to compare thymus-linked immunomodulatory signatures across distinct dipeptides
• Crystagen (Glu-Asp-Pro) → to broaden immune-aging and lymphocyte-proliferation endpoint panels
• Glutathione → to expand oxidative-stress and antioxidant-defense panels in immune stress-challenge models

Stacks discussed are for experimental design only, not safety/efficacy guidance.

Possible Side Effects

There are no known reports of negative side effects.

Scientific References

• The Use of Thymalin for Immunocorrection and Molecular Aspects of Immunoprotective Action — Review (Human/Preclinical)
• The effect of vilon on the thymus and spleen in a radiation model — Animal
• Age-related molecular aspects of immunomodulating activity of vilon and related dipeptides in thymic cells — In vitro
• Application of peptide bioregulator in complex treatment of elderly cancer patients (Vilon included) — Human (Observational)
• A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice — Animal
• Age-related molecular aspects of immunomodulating activity of short peptides (includes Vilon) — In vitro/Animal
• Inhibitory Effect of Peptide Vilon on the Development of Urinary Bladder Carcinogenesis in Rats — Animal
• Peptide Regulation of Gene Expression: A Systematic Review — Systematic review
• Peptides: Prospects for Use in the Treatment of COVID-19 — Review (Human/Preclinical)
• Lysylglutamic acid (Lys-Glu; Vilon/KE) — PubChem compound record — Reference (Chemical)

Cautions

• For educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.
• If you are pregnant, nursing, have a medical condition, or use prescription medication, consult a qualified professional.
• Discontinue use if sensitivity occurs.